SG11202012697QA - Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor - Google Patents
Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitorInfo
- Publication number
- SG11202012697QA SG11202012697QA SG11202012697QA SG11202012697QA SG11202012697QA SG 11202012697Q A SG11202012697Q A SG 11202012697QA SG 11202012697Q A SG11202012697Q A SG 11202012697QA SG 11202012697Q A SG11202012697Q A SG 11202012697QA SG 11202012697Q A SG11202012697Q A SG 11202012697QA
- Authority
- SG
- Singapore
- Prior art keywords
- krasg12c
- mutein
- pyridone
- inhibitor
- pyrimidine derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810055396 | 2018-01-19 | ||
| CN201810712103 | 2018-06-29 | ||
| PCT/CN2019/072393 WO2019141250A1 (en) | 2018-01-19 | 2019-01-18 | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012697QA true SG11202012697QA (en) | 2021-02-25 |
Family
ID=67301292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012697QA SG11202012697QA (en) | 2018-01-19 | 2019-01-18 | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| SG10202102462SA SG10202102462SA (en) | 2018-01-19 | 2019-01-18 | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202102462SA SG10202102462SA (en) | 2018-01-19 | 2019-01-18 | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11453667B2 (en) |
| EP (2) | EP3842433B1 (en) |
| JP (2) | JP7289839B2 (en) |
| CN (4) | CN112442030B (en) |
| SG (2) | SG11202012697QA (en) |
| WO (1) | WO2019141250A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3842433B1 (en) | 2018-01-19 | 2023-11-01 | Medshine Discovery Inc. | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| CN113227089A (en) | 2018-10-31 | 2021-08-06 | 吉利德科学公司 | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors |
| TWI721624B (en) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | Substituted 6-azabenzimidazole compounds |
| US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| EP4043464A4 (en) * | 2019-09-20 | 2023-10-04 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | Fused pyridone compound, and preparation method therefor and use thereof |
| WO2021058018A1 (en) * | 2019-09-29 | 2021-04-01 | Beigene, Ltd. | Inhibitors of kras g12c |
| CN113286794B (en) * | 2019-11-04 | 2024-03-12 | 北京加科思新药研发有限公司 | KRAS mutein inhibitors |
| CN112824410A (en) * | 2019-11-21 | 2021-05-21 | 苏州泽璟生物制药股份有限公司 | Aza-heptacyclic inhibitor and preparation method and application thereof |
| CN113651814B (en) * | 2019-12-19 | 2022-06-17 | 北京加科思新药研发有限公司 | KRAS mutein inhibitors |
| CN113527293B (en) * | 2020-04-20 | 2023-09-08 | 苏州璞正医药有限公司 | KRAS G12C mutant protein inhibitor, pharmaceutical composition, preparation method and application thereof |
| CN111423366B (en) * | 2020-04-28 | 2022-05-27 | 山东汇海医药化工有限公司 | Preparation method of pirfenidone |
| CN113880827A (en) * | 2020-07-03 | 2022-01-04 | 苏州闻天医药科技有限公司 | Compound for inhibiting KRASG12C mutant protein and preparation method and application thereof |
| WO2022048545A1 (en) * | 2020-09-01 | 2022-03-10 | 勤浩医药（苏州）有限公司 | Crystal form of pyridopyrimidine compound |
| CN116133662A (en) * | 2020-09-11 | 2023-05-16 | 南京明德新药研发有限公司 | Crystalline forms of azetidine-substituted compounds |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022222871A1 (en) * | 2021-04-21 | 2022-10-27 | Beijing Innocare Pharma Tech Co., Ltd. | Heterocyclic compounds as kras g12c inhibitors |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| TW202317100A (en) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
| TW202327569A (en) | 2021-09-01 | 2023-07-16 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| WO2023138662A1 (en) * | 2022-01-21 | 2023-07-27 | 南京明德新药研发有限公司 | Benzopyrimidine compounds and use thereof |
| WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN117430620A (en) * | 2022-07-22 | 2024-01-23 | 上海医药集团股份有限公司 | Pyrimidine ring compound, intermediate thereof, pharmaceutical composition thereof and application of pharmaceutical composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013144283A1 (en) * | 2012-03-30 | 2013-10-03 | Orthodontic Research And Development, S.L. | Method of assembling a distalizer |
| BR112016008016B8 (en) * | 2013-10-10 | 2023-09-26 | Araxes Pharma Llc | kras g12c inhibitory compounds, pharmaceutical composition comprising said compounds, methods for regulating the activity and for preparing a kras, hras or nras g12c mutant protein, method for inhibiting the proliferation of a population of cells and therapeutic uses of said compounds |
| KR20180005178A (en) * | 2015-04-10 | 2018-01-15 | 아락세스 파마 엘엘씨 | Substituted quinazoline compounds and methods for their use |
| WO2016168540A1 (en) | 2015-04-15 | 2016-10-20 | Araxes Pharma Llc | Fused-tricyclic inhibitors of kras and methods of use thereof |
| TW201726656A (en) * | 2015-11-16 | 2017-08-01 | 亞瑞克西斯製藥公司 | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| WO2017100546A1 (en) * | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| CA3024523A1 (en) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| US10280172B2 (en) * | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| SG11201906223TA (en) | 2016-12-22 | 2019-08-27 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| JP7327802B2 (en) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | Fused hetero-heterobicyclic compounds and methods of use thereof |
| CA3061650A1 (en) | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| EP3842433B1 (en) | 2018-01-19 | 2023-11-01 | Medshine Discovery Inc. | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
-
2019
- 2019-01-18 EP EP21155251.8A patent/EP3842433B1/en active Active
- 2019-01-18 CN CN202011378149.5A patent/CN112442030B/en active Active
- 2019-01-18 CN CN202011378153.1A patent/CN112442031B/en active Active
- 2019-01-18 SG SG11202012697QA patent/SG11202012697QA/en unknown
- 2019-01-18 SG SG10202102462SA patent/SG10202102462SA/en unknown
- 2019-01-18 US US16/962,951 patent/US11453667B2/en active Active
- 2019-01-18 EP EP19740933.7A patent/EP3741756B1/en active Active
- 2019-01-18 CN CN201980009147.8A patent/CN111630053A/en active Pending
- 2019-01-18 WO PCT/CN2019/072393 patent/WO2019141250A1/en unknown
- 2019-01-18 CN CN202110310525.5A patent/CN113121530B/en active Active
- 2019-01-18 JP JP2020539829A patent/JP7289839B2/en active Active
-
2021
- 2021-01-27 US US17/159,928 patent/US11655248B2/en active Active
- 2021-02-05 JP JP2021017606A patent/JP7352587B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3842433B1 (en) | 2023-11-01 |
| CN113121530B (en) | 2022-08-05 |
| EP3842433A1 (en) | 2021-06-30 |
| CN112442030B (en) | 2022-09-27 |
| US11453667B2 (en) | 2022-09-27 |
| JP7289839B2 (en) | 2023-06-12 |
| CN112442030A (en) | 2021-03-05 |
| JP2021091691A (en) | 2021-06-17 |
| JP2021510721A (en) | 2021-04-30 |
| US20210147418A1 (en) | 2021-05-20 |
| EP3741756A4 (en) | 2020-12-09 |
| EP3741756A1 (en) | 2020-11-25 |
| SG10202102462SA (en) | 2021-04-29 |
| JP7352587B2 (en) | 2023-09-28 |
| US11655248B2 (en) | 2023-05-23 |
| CN112442031B (en) | 2022-07-12 |
| CN112442031A (en) | 2021-03-05 |
| WO2019141250A1 (en) | 2019-07-25 |
| CN113121530A (en) | 2021-07-16 |
| US20210371411A1 (en) | 2021-12-02 |
| EP3741756B1 (en) | 2023-11-01 |
| CN111630053A (en) | 2020-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202012697QA (en) | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor | |
| SG11202004918XA (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| IL269803A (en) | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor | |
| IL275207A (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| IL277455A (en) | Aminopyrimidine derivatives as ctps1 inhibitors | |
| GB202201999D0 (en) | Interleukin-2 Derivative | |
| IL283197A (en) | Microbiocidal 2-acylamino-thiazole-4-carboxamide derivatives | |
| IL283990A (en) | Substituted oxopyridine derivatives | |
| SG11202101622VA (en) | Novel quinoline derivative inhibitor | |
| IL281634A (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
| IL289197A (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| IL279938A (en) | Spirochromane derivatives | |
| IL290964A (en) | 2-aminoquinazolinone derivative | |
| IL290815A (en) | Alpha-d-galactopyranoside derivatives | |
| SI3796975T1 (en) | Sulfonylaminobenzamide derivatives | |
| EP3712157A4 (en) | Pyridopyrimidine compounds acting as mtorc 1/2 double-kinase inhibitors | |
| SG11202007979UA (en) | Dihydrochromene derivative | |
| SG11202006837XA (en) | Dihydroindolizinone derivative | |
| EP3885347A4 (en) | Dihydropyrrolopyrazole derivative | |
| EP3640250A4 (en) | Compound as gls1 inhibitor | |
| GB201919210D0 (en) | Dihydro-cyclopenta-isoquinoline derivatives | |
| EP3872061A4 (en) | 1-phenyl-2-phenylethane derivative | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201806948D0 (en) | Derivatives |